---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010658"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:40:18.538524+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MetaVia Q2 net loss $4.0M; cash $17.6M; DA-1726 48mg data expected Q4 2025

## Summary
- Net loss $4.0M ($0.26/sh) vs $10.1M ($1.85/sh) in Q2 2024; R&D expenses fell to $2.3M from $8.1M.
- Cash $17.6M as of June 30, 2025, expected to fund operations into 2026.
- Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data due Q4 2025.
- Signed AI collaboration with Syntekabio to identify new indications for DA-1241 beyond MASH.
- Closed $10.0M private placement in May 2025 with Dong-A ST and Dong-A Socio Holdings.

## SEC filing metadata
- accession: 0001558370-25-010658
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/0001558370-25-010658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010658
- JSON: https://secwatch.observer/filing/0001558370-25-010658.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.